Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAPDH | P04406 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9912435 | 0.83 | GAPDH (0.58) | GAPDHL3MBTL1KMT2AATMKDM4E | |
| SCHEMBL1428340 | 0.81 | GAPDH (0.56) | GAPDHL3MBTL1KMT2AATMKDM4E | |
| SCHEMBL4109619 | 0.81 | ATM (0.58) | GAPDHL3MBTL1KMT2AATMKDM4E | |
| SCHEMBL13149779 | 0.79 | GAPDH (0.57) | GAPDHL3MBTL1KMT2AATMKDM4E | |
| SCHEMBL13059408 | 0.79 | ATM (0.59) | GAPDHL3MBTL1ATMKDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL3090336 | 0.77 | GAPDH (0.56) | GAPDHL3MBTL1KMT2AATMKDM4E | |
| SCHEMBL13002465 | 0.77 | GAPDH (0.52) | GAPDHL3MBTL1KMT2AATMKDM4E | |
| SCHEMBL19116648 | 0.77 | SMN1; SMN2 (0.58) | GAPDHL3MBTL1ATMALDH1A1RAB9A | |
| SCHEMBL1033633 | 0.77 | GAPDH (0.52) | GAPDHL3MBTL1ATMKDM4EALDH1A1 | |
| SCHEMBL12630123 | 0.77 | ATM (0.54) | GAPDHL3MBTL1ATMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025093589-A1 | HETEROARYL AMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-05-08 | — | — | WO | disclosed |
| CN-107252429-B | Novel anti-inflammatory agent | 雷斯韦洛吉克斯公司 | 2023-06-16 | — | — | CN | disclosed |
| EP-3431086-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2020-06-17 | — | — | EP | disclosed |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2020-04-30 | — | — | US | disclosed |
| EP-3431086-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | Resverlogix Corp. (CA) | 2019-01-23 | — | — | EP | disclosed |
| EP-2421533-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2018-10-17 | — | — | EP | disclosed |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2017-11-23 | — | — | US | disclosed |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2017-11-16 | — | — | US | disclosed |
| US-9757368-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2017-09-12 | — | — | US | disclosed |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | RVX THERAPEUTICS INC. (CA) | 2013-10-24 | — | — | US | disclosed |
| WO-2008059239-A1 | NOVEL COMPOUNDS 514 | ASTRAZENECA AB (SE) | 2008-05-22 | — | — | WO | disclosed |
| EP-1831208-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | Novartis AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1831202-A1 | PYRROLINIDIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS | Novartis AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1811999-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2007-08-01 | — | — | EP | disclosed |
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | NOVARTIS AG (CH) | 2007-03-15 | — | — | US | disclosed |
| WO-2006066929-A1 | QUATERNARY AMMONIUM SALTS AS M3 ANTAGONISTS | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006066928-A1 | PYRROLINIDIUM DERIVATIVES AS M3 MUSCARINIC RECEPTORS | NOVARTIS AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| WO-2006048225-A1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| EP-1631569-A2 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | Novartis AG (CH) | 2006-03-08 | — | — | EP | disclosed |
| WO-2004096800-A2 | QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS | NOVARTIS AG (CH) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060563-A1 | Quinuclidine derivatives binding to mucarinic m3 receptors | CHRM3, CHRM2, CHRM1 | GAPDH 4028/4885L3MBTL1 3806/4885KMT2A 2755/4885 |
| US-20130281398-A1 | TREATMENT OF DISEASES BY EPIGENETIC REGULATION | PHKB, BAZ2A, EP300 | GAPDH 1949/4885L3MBTL1 659/4885KMT2A 199/4885 |
| US-20170326143-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | GAPDH 3703/4885L3MBTL1 4280/4885KMT2A 3505/4885 |
| US-20170333419-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | GAPDH 3703/4885L3MBTL1 4280/4885KMT2A 3505/4885 |
| US-20200129512-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | GAPDH 3703/4885L3MBTL1 4280/4885KMT2A 3505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.